Immunoglobulin Or Antibody Is Anti-idiotypic Patents (Class 435/327)
-
Publication number: 20040156839Abstract: This invention describes the design and therapeutic use of antisense peptides for immunomodulation. Specifically applications include blocking the interaction of immunoglobulin G (IgG) with Fc&ggr; receptors (FC&ggr;R) and blocking the interaction of immunoglobulin E (IgE) with Fc&egr;RI or IgA with Fc&agr;RI. This invention also describes the application of antisense peptides to target vaccines to Fc&ggr;R to induce or suppress immunity, and also describes the application of antisense peptide specific for Fc&ggr;R or Fc&agr;RI to direct cytotoxic effector cells to target cells or pathogens.Type: ApplicationFiled: February 17, 2004Publication date: August 12, 2004Inventors: Katherine Lucy Dry, Joseph Michael Sheridan, John Graham Raynes
-
Publication number: 20040156843Abstract: The present invention provides a treatment for mammalian diseases characterized by pathological angiogenesis. The treatment consists of administering therapeutically active dosages of peptides containing specific amino acid sequences or antibodies that bind to cell membrane antigens on the surface of rapidly dividing endothelial cells.Type: ApplicationFiled: March 23, 2004Publication date: August 12, 2004Inventor: Adonia E. Papathanassiu
-
Publication number: 20040146504Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.Type: ApplicationFiled: January 5, 2004Publication date: July 29, 2004Applicants: Pfizer, Inc., Pfizer Products, Inc.Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
-
Publication number: 20040146991Abstract: Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.Type: ApplicationFiled: March 10, 2004Publication date: July 29, 2004Applicant: Japan Tobacco, Inc., a Japan corporationInventors: Takashi Tsuji, Katsunari Tezuka, Nobuaki Hori
-
Publication number: 20040052783Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.Type: ApplicationFiled: May 9, 2003Publication date: March 18, 2004Applicants: Protein Design Labs, Inc., Iowa Immunotherapy InvestigatorsInventors: George Weiner, Roger Gingrich, Brian K. Link, J. Yun Tso
-
Publication number: 20040047858Abstract: Provided are specific antibodies which are capable of modulating T cell activity and uses thereof. In particular, antibodies and binding fragments thereof are described, which react with a specific domain of biliary glycoprotein (BGP), also known as CD66a, CEACAM1 and C-CAM1, and which are capable of suppressing the cytolytic activity of intestinal intraepithelial lymphocytes (iIELs). Furthermore, compositions comprising said antibodies are provided and methods of modulating immune cell proliferation, and treating immune response related diseases.Type: ApplicationFiled: September 11, 2002Publication date: March 11, 2004Inventors: Richard S. Blumberg, Atul Bhan
-
Publication number: 20040038308Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.Type: ApplicationFiled: June 3, 2003Publication date: February 26, 2004Inventors: Russell Rother, Dayang Wu
-
Publication number: 20030223989Abstract: There are disclosed methods for treating conditions mediated by IgE, comprising administering a CD137 agonist to a mammal afflicted with such a condition. CD137 agonists include CD137 ligand (CD137L) and agonistic antibodies to CD137; mammals to be treated include humans. Conditions mediated by IgE include asthma, atopic dermatitis, and allergy. CD137 agonists are also useful for treating conditions characterized by delayed eosinophil apoptosis, including nasal polyps and hypereosinophilic syndrome. Patients to be treated may be afflicted with, or at risk for, one or more of these conditions.Type: ApplicationFiled: April 18, 2003Publication date: December 4, 2003Inventor: John D. Pluenneke
-
Publication number: 20030175837Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.Type: ApplicationFiled: July 2, 2001Publication date: September 18, 2003Applicant: New York University Medical CenterInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Publication number: 20030147881Abstract: This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.Type: ApplicationFiled: October 17, 2002Publication date: August 7, 2003Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Nai-Kong V. Cheung, Hong-Fen Guo
-
Patent number: 6573096Abstract: The invention provides antibodies to a membrane protease complex, consisting of two homodimers of seprase and dipeptidyl peptidase IV (DPPIV), obtained from human cell membranes. The antibodies specifically bind the DPPIV protease of the seprase-DPPIV complex that resides on cell surface invadopodia at the leading edge of angiogenic endothelia, migratory fibroblasts, and invading cancer cells, while failing to react with resting cells in adjacent human tissues and blood vessels. These antibodies block interaction of collagen matrix with the seprase-DPPIV complex in the invasive cells during angiogenesis and cancer spreading but not that with other endothelia or tumor cells. The invention further provides methods of using DPPIV antagonists to inhibit capillary sprouting, angiogenesis and cancer invasion in tumor tissues and metastases. Also provided are therapeutic compositions comprising DPPIV antagonists.Type: GrantFiled: April 3, 2000Date of Patent: June 3, 2003Assignee: The Research Foundation at State University of New YorkInventor: Wen-Tien Chen
-
Publication number: 20030100741Abstract: Nucleotide sequences encoding the variable heavy and light chains of the murine monoclonal antibody 1F7 are disclosed. The 1F7 antibody is an effective immune modulator that has anti-idiotypic binding affinity for anti-HIV antibodies. Polypeptides containing at least one complementarity-determining region (CDR) or framework-determining region (FR) of the variable heavy or variable light chains of 1F7, as well as the polynucleotides encoding them, can be used to modulate the immune response to HIV infection. Unnecessary, and potentially adverse, murine segments of the variable chains falling outside the CDRs can be replaced with human sequences to afford humanized chimeric antibodies and antibody fragments.Type: ApplicationFiled: January 11, 2001Publication date: May 29, 2003Inventors: Sybille Muller, Heinz Kohler
-
Publication number: 20030095964Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.Type: ApplicationFiled: October 8, 2002Publication date: May 22, 2003Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20030092065Abstract: There is provided a novel peptide, a method of screening using the peptide, and an antibody obtained by the method of screening.Type: ApplicationFiled: July 9, 2002Publication date: May 15, 2003Inventors: Naohiro Washida, Ken Takahashi, Toshiko Satake, Nobuaki Fujise, Hideki Tanaka, Masayoshi Kuriyama
-
Publication number: 20030077275Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).Type: ApplicationFiled: August 5, 2002Publication date: April 24, 2003Applicant: IDEC Pharmaceuticals CorporationInventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
-
Publication number: 20030064063Abstract: The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis.Type: ApplicationFiled: October 24, 2001Publication date: April 3, 2003Inventor: Andrew Saxon
-
Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
Publication number: 20030035797Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.Type: ApplicationFiled: August 13, 2002Publication date: February 20, 2003Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Paul B. Chapman, Alan N. Houghton -
Patent number: 6479639Abstract: A hybridoma (termed “UIC2 hybridoma”, ATCC Accession No. HB11027) producing monoclonal antibodies (termed “UIC2 mAb”) directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a BALB/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdrl cDNA. UIC2 mAb, thus produced, as well as fragments and recombinant derivatives thereof, may be used to detect and isolate multidrug resistant primate cells and human mdrl gene products, and to reverse multidrug resistance in primate cells, including cells of multidrug resistant human tumors.Type: GrantFiled: February 29, 2000Date of Patent: November 12, 2002Assignee: Board of Trustees for the University of IllnoisInventors: Eugene Metchetner, Igor B. Roninson
-
Patent number: 6475775Abstract: The invention describes nucleic acids encoding the PARG protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.Type: GrantFiled: May 8, 2000Date of Patent: November 5, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Jan Saras, Petra Franzén, Pontus Aspenström, Ulf Hellman, Leonel Jorge Gonez, Carl-Henrik Heldin
-
Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
Patent number: 6432402Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.Type: GrantFiled: May 23, 1995Date of Patent: August 13, 2002Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Paul B. Chapman, Alan N. Houghton -
Patent number: 6413726Abstract: The invention relates to Cytostatin III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: GrantFiled: December 12, 2000Date of Patent: July 2, 2002Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Reiner Gentz, Patrick J. Dillon
-
Publication number: 20020028200Abstract: The present invention relates to an anti-idiotypic antibody or antigen-binding fragment against FimH adhesin of uropathogenic Type I-fimbriated Escherichia coli and an immunizing composition containing such an anti-idiotypic antibody or antigen-binding fragment thereof as an active immunizing component. The present invention also relates to a method for stimulating and enhancing the production of antibodies which recognize and bind to FimH of uropathogenic Type-I-fimbriated Escherichia coli, but not to FimH of non-uropathogenic Type I-fimbriated Escherichia coli.Type: ApplicationFiled: May 10, 2001Publication date: March 7, 2002Inventor: Xue-Ru Wu
-
Publication number: 20020009442Abstract: The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.Type: ApplicationFiled: July 25, 2001Publication date: January 24, 2002Inventors: Sybille Muller, Haitao Wang
-
Publication number: 20010047083Abstract: The present invention provides a monoclonal anti-idiotype antibody 3H1 that escapes immune tolerance and elicits a specific immune response to CEA in mice, rabbits, monkeys, and patients with advanced CEA-associated disease. This invention also provides compositions which can be used in the detection or treatment of CEA-associated tumors mimics a specific epitope on carcinoembryonic antigen and a hybridoma that produces 3H1.Type: ApplicationFiled: February 28, 2001Publication date: November 29, 2001Inventors: Malaya Chatterjee, Heinz Kohler, Sunil K. Chatterjee, Kenneth A. Foon
-
Publication number: 20010039332Abstract: Hybridoma cell lines have been generated which produce and secrete monoclonal antibodies which selectively bind to 4,4′-dinitrocarbanilide (DNC), the active agent of nicarbazin. These hybridomas may be obtained by using as an immunization agent or immunogen, p-nitroaniline which has been conjugated to an immunogenic carrier. DNC in biological samples may be detected and quantified by contacting the sample with the antibodies to form a DNC/antibody immunocomplex when DNC is present, which immunocomplex may then be detected. The monoclonal antibodies also may be incorporated into kits for the detection and quantification of DNC and/or nicarbazin.Type: ApplicationFiled: November 29, 2000Publication date: November 8, 2001Inventors: Ross C. Beier, Larry H. Stanker, Colin R. Young
-
Patent number: 6306615Abstract: This invention relates to monoclonal antibodies that recognize modified &bgr;-tubulin isotypes, methods of using such antibodies to detect modified &bgr;-tubulin isotypes, methods of using such antibodies to monitor &bgr;-tubulin modifying agents administered to a patient, methods of using such antibodies to isolate modified &bgr;-tubulin, and methods of detecting the anti-modified &bgr;-tubulin antibodies.Type: GrantFiled: August 19, 1999Date of Patent: October 23, 2001Assignee: Tularik Inc.Inventors: Holger Beckmann, Edit Santha
-
Patent number: 6306608Abstract: An antibody reacting specifically with human LECT2. This antibody is produced by hybridoma clones G2A5D7 (Accession No. FERM P-15638), A1G1C6 (Accession No. FERM P-15639), 5C5 (Accession No. FERM P-15640), H12D10D6 (Accession No. FERM P-15641), etc. Human LECT2 can be assayed by reacting human LECT2 successively with an immobilized antibody which has been formed by binding the above-mentioned antibody to an insoluble support and a labeled antibody which has been formed by labeling another antibody reacting with human LECT2 with a labeling agent, and then determining the amount of label in the reaction product.Type: GrantFiled: November 25, 1998Date of Patent: October 23, 2001Assignee: Medical & Biological Laboratories Co., Ltd.Inventor: Takao Arai
-
Publication number: 20010010901Abstract: The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.Type: ApplicationFiled: February 28, 2001Publication date: August 2, 2001Inventors: Sybille Muller, Haitao Wang
-
Patent number: 6232444Abstract: Methods and antibody compositions are provided for the diagnosis and treatment of lupus nephritis. By employing B-cells of a lupus nephritis host with a fusion partner, antibodies can be obtained, which may serve as immunogens for the production of antiidiotypic antibodies, which may then be used for diagnosis and therapy of lupus nephritis.Type: GrantFiled: April 8, 1996Date of Patent: May 15, 2001Assignee: The Regents of the University of CaliforniaInventor: Richard Weisbart
-
Patent number: 6193982Abstract: The present invention provides an anti-cyanovirin antibody with an internal image of gp120, a method of using an anti-cyanovirin antibody with an internal image of gp120 to induce an immune response to gp120 so as to prevent or treat a viral infection in an animal, and a method of using a cyanovirin to induce an immune response to gp120 so as to prevent or treat a viral infection in an animal.Type: GrantFiled: August 19, 1998Date of Patent: February 27, 2001Assignee: The United States of America as represented by the Department of Health & Human ServicesInventor: Michael R. Boyd
-
Patent number: 6074641Abstract: The present invention relates to anti-idiotypic antibodies directed against Neisseria gonorrhoeae. This invention also relates to methods and compositions using such anti-idiotypic antibodies for the prophylaxis, treatment and diagnosis of gonorrheal infections.Type: GrantFiled: March 29, 1999Date of Patent: June 13, 2000Inventors: Peter A. Rice, Sunita Gulati, Daniel P. McQuillen
-
Patent number: 6066718Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.Type: GrantFiled: September 27, 1993Date of Patent: May 23, 2000Assignees: Novartis Corporation, Tanox Biosystems, Inc.Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha
-
Patent number: 6057421Abstract: The amino acid sequences of variable heavy and variable light domains of murine monoclonal antibody 1F7 are reported. Methods of use for products containing these sequences in the diagnosis and the treatment of HIV infection and AIDS are also described.Type: GrantFiled: December 3, 1997Date of Patent: May 2, 2000Assignee: Immpheron, Inc.Inventors: Sybille Muller, Heinz Kohler
-
Patent number: 6042827Abstract: Novel compositions and methods are described for stimulating a patient's immune system to tumor cells which bear a gp72 tumor-associated antigen and thereby eliciting a tumoricidal effect. Anti-idiotypic human monoclonal antibodies and idiotopic regions thereof to primary antibodies which bind selectively to an antigenic determinant of gp72 are provided to mediate the humoral and cellular components of the patient's immune system. The immunogenic agents find use both in vivo and in vitro.Type: GrantFiled: July 21, 1994Date of Patent: March 28, 2000Assignee: Cancer Research Campaign Technology LimitedInventors: Robert William Baldwin, Linda Gillian Durrant, Eric Bertram Austin, Vera S. Byers
-
Patent number: 5977315Abstract: The present invention provides a monoclonal anti-idiotype antibody 3H1 that escapes immune tolerance and elicits a specific immune response to CEA in mice, rabbits, monkeys, and patients with advanced CEA-associated disease. This invention also provides compositions which can be used in the detection or treatment of CEA-associated tumors mimics a specific epitope on carcinoembryonic antigen and a hybridoma that produces 3H1.Type: GrantFiled: December 28, 1995Date of Patent: November 2, 1999Assignee: The Board of Trustees of the University of KentuckyInventors: Malaya Chatterjee, Heinz Kohler, Sunil K. Chatterjee, Kenneth A. Foon
-
Patent number: 5972334Abstract: The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.Type: GrantFiled: December 6, 1996Date of Patent: October 26, 1999Assignee: Genitope CorporationInventor: Dan W. Denney, Jr.
-
Patent number: 5935821Abstract: The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence.Type: GrantFiled: November 21, 1996Date of Patent: August 10, 1999Assignee: Board of Trustees of the University of KentuckyInventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Patent number: 5885576Abstract: The present invention provides an immunogenic compound comprising the formula: ##STR1## wherein X is selected from the group consisting of methyl and hydrogen; wherein R.sub.1 is a suitable functional group of the lysergic ring;wherein R.sub.2 is an immunogenic protein; andwherein Y is a bridge to link R.sub.1 to R.sub.2.The present invention also provides purified polyclonal and monoclonal antibodies specifically reactive with the immunogenic compound and reactive with the lysergic ring of ergopeptine and clavine alkaloids. The present invention further provides an antibody which is an anti-idiotype of the monoclonal antibody. Also provided are methods of prevention and treatment of fescue toxicosis utilizing the immunogenic compounds and antibodies of the present invention.Type: GrantFiled: June 7, 1995Date of Patent: March 23, 1999Assignees: The United States of America as represented by the Secretary of Agriculture, The University of Georgia Research Foundation, Inc.Inventors: Nicholas S. Hill, Frederick N. Thompson, Jr., John A. Stuedemann, Donald L. Dawe
-
Patent number: 5858361Abstract: Disclosed is an anti-idiotypic antibody which reacts with an anti-CA125 antibody and competes with CA125 in its binding to said anti-idiotypic antibody are disclosed which have essentially the same binding specificity. Additionally, the invention relates to cell lines, particularly to hybridoma 3D5 (DSM ACC2120), producing said anti-idiotypic antibodies. Also disclosed are pharmaceutical compositions containing said anti-idiotypic antibodies and specific uses of these antibodies.Type: GrantFiled: February 26, 1996Date of Patent: January 12, 1999Inventors: Uwe Wagner, Harald Schlebusch
-
Patent number: 5854069Abstract: Three murine monoclonal anti-idiotype antibodies which functionally mimic GD2 are described. These antibodies are useful in compositions for inducing a CD4 T cell response to cancers characterized by high density GD2 expression and in the diagnosis of high density GD2 expression.Type: GrantFiled: April 18, 1997Date of Patent: December 29, 1998Assignee: The Wistar Institute of Anatomy & BiologyInventor: Dorothee Herlyn
-
Patent number: 5849583Abstract: The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.Type: GrantFiled: August 20, 1993Date of Patent: December 15, 1998Assignee: Sidney Kimmel Cancer CenterInventors: Sybille Muller, Haitao Wang
-
Patent number: 5847088Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: ICOS CorporationInventors: Lawrence S. Cousens, Christine D. Eberhardt, Patrick Gray, Hai Le Trong, Larry W. Tjoelker, Cheryl L. Wilder
-
Patent number: 5840297Abstract: A genus specific chlamydia vaccine is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-anti-idiotypic antibody which recognizes a glycoplipid exoantigen (GLXA) of chlamydia. The vaccine is produced by producing an idiotypic antibody to GLXA which, in turn, is utilized t produce the anti-idiotypic antibody comprising the vaccine.Type: GrantFiled: March 19, 1993Date of Patent: November 24, 1998Assignees: Johns Hopkins University, University of MassachusettsInventors: Alex Bruce MacDonald, Ling-Ling An, Elizabeth Sutton-Stuart, Judith A. Whittum-Hudson
-
Patent number: 5830681Abstract: Monoclonal antibodies and fragments thereof, with binding specificity for an epitope on the carboxy terminus of prothrombin activation peptide F1.2, which can be used in immunoassays to predict thrombosis by measuring the extent of activation of prothrombin. These monoclonal antibodies are also included in a kit for performing such immunoassays.Type: GrantFiled: December 30, 1993Date of Patent: November 3, 1998Assignee: Akzo Nobel N.V.Inventors: Marcie J. Hursting, Bryan T. Butman, Jerald P. Steiner, Bryant M. Moore, Frederick A. Dombrose
-
Patent number: 5785966Abstract: Reactivity between an alloantigen and an anti-alloantigen is indicative of immunological reactivity between two biological samples of the same species. Reactivity between a xenoantigen and an anti-xenoantigen is indicative of immunological reactivity between two biological samples of different species. In many cases both of the reactions are indicative of an antibody-mediated rejection. Anti-antibodies can be employed to reduce cross-reactivity in many transplantation-type situations, either within a similar species, or across species lines. These anti-antibodies are prepared against the antibodies responsible for the antibody-mediated rejection. These anti-antibodies can then be used in vivo or in vitro to complex with the antibodies thus reducing or eliminating reactivity between an alloantigen and an anti-alloantigen or reactivity between a xenoantigen and an anti-xenoantigen between any two species combinations.Type: GrantFiled: June 15, 1994Date of Patent: July 28, 1998Inventors: John G. Coles, Miyoko Takahashi, David S. F. Young, Inka Brockhausen
-
Patent number: 5780029Abstract: The invention concerns murine antiidiotypic monoclonal antibodies which are the internal image of determinants recognized by a monoclonal antibody on high molecular weight-melanoma associated antigen (HMW-MAA), antibody derivatives, hybridoma cell lines secreting such antiidiotypic monoclonal antibodies, and processes for the preparation of such antiidiotypic monoclonal antibodies, of their derivatives and of the hybridoma cell lines. The murine antiidiotypic monoclonal antibodies are useful for the determination of antibodies directed against high molecular weight-melanoma associated antigen, for the modulation of the immune response to HMW-MAA and for the treatment of melanoma.Type: GrantFiled: October 27, 1995Date of Patent: July 14, 1998Assignee: New York Medical CollegeInventor: Soldano Ferrone
-
Patent number: 5766588Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor.Type: GrantFiled: September 22, 1995Date of Patent: June 16, 1998Assignee: OncogenInventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Victor K. Lee
-
Patent number: 5717073Abstract: The invention relates to anti-gp130 monoclonal antibodies, as well as to their uses for obtaining medicinal products, cell culture adjuvants and diagnostic reagents.Type: GrantFiled: April 18, 1996Date of Patent: February 10, 1998Assignee: Diaclone S.A. a Directoire et Conseil de SurveillanceInventors: John Wijdenes, Claude Clement
-
Patent number: 5653977Abstract: The invention provides an anti-idiotypic monoclonal antibody which elicits an immune response in a mammal against the ganglioside GD2 antigen.Type: GrantFiled: October 23, 1995Date of Patent: August 5, 1997Assignee: UAB Research FoundationInventor: Mansoor N. Saleh
-
Patent number: 5637493Abstract: Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.Type: GrantFiled: February 24, 1994Date of Patent: June 10, 1997Assignees: Sci-Clone, Inc., The Regents of the University of CaliforniaInventors: Mark C. Glassy, Helena R. Chang, Keiji Koda